Market Access Lessons For Cell And Gene Therapies In Germany

Companies Can Learn From Bluebird Bio’s Failed Zynteglo Pricing Deal

 
• By Alexander Natz

Lawyer and industry expert Alexander Natz sets out some important dos and don’ts for securing a successful launch of an advanced therapy in Germany.

German Flag
Zynteglo offers a cautionary tale for launching ATMPs in Germany • Source: Alamy

Unhappy with the price that was to be allowed in Germany for its gene therapy Zynteglo, bluebird bio withdrew the product from the market.

About The Author

Dr Alexander Natz is a lawyer and the founder of the Düsseldorf-based law firm Novacos Rechtsanwälte. Email: alexander.natz@novacos-law.com

More from Europe

More from Geography